510(k) Data Debated In Comments On FDA Draft Guidance
This article was originally published in The Gray Sheet
Executive Summary
Device companies say non-clinical data should be given more prominence in FDA guidance on benefit-risk factors to consider when determining substantial equivalence of 510(k) devices with different technological characteristics from a predicate. But a coalition of consumer groups argues that the draft guidance underplays the need for clinical data.